Application of the Failure Mode and Effects Analysis (FMEA) to identify vulnerabilities and opportunities for improvement prior to implementing a computerized prescription order entry (CPOE) system in a university hospital oncology clinic
- 9 November 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 88-95
Abstract
Introduction: Prior to implementing a new computerized prescription order entry (CPOE) application, the potential risks associated with this system were assessed and compared to those of paper-based prescriptions. The goal of this study is to identify the vulnerabilities of the CPOE process in order to adapt its design and prevent these potential risks. Methods and materials: Failure mode and effects analysis (FMEA) was used as a prospective risk-management technique to evaluate the chemotherapy medication process in a university hospital oncology clinic. A multidisciplinary team assessed the process and compared the critical steps of a newly developed CPOE application versus paper-based prescriptions. The potential severity, occurrence and detectability were assessed prior to the implementation of the CPOE application in the clinical setting. Results: The FMEA led to the identification of 24 process steps that could theoretically be vulnerable, therefore called failure modes. These failure modes were grouped into four categories of potential risk factors: prescription writing, patient scheduling, treatment dispensing and patient follow-up. Criticality scores were calculated and compared for both strategies. Three failure modes were prioritized and led to modification of the CPOE design. Overall, the CPOE pathway showed a potential risk reduction of 51% compared to paper-based prescriptions. Conclusion: FMEA was found to be a useful approach to identify potential risks in the chemotherapy medication process using either CPOE or paper-based prescriptions. The e-prescription mode was estimated to result in less risk than the traditional paper mode.Keywords
Funding Information
- AstraZeneca Canada
- F. Hoffmann-La Roche
- Takeda Pharmaceuticals North America
- Novartis Pharmaceuticals Canada
- Celgene
- Bristol-Myers Squibb Canada
- Merck Canada
- Ministere de l'Economie et de l'Innovation du Quebec
- Pfizer Oncology
- Eli Lilly Canada
- Astellas Pharma Canada
- Seattle Genetics
- Amgen Canada
- Gilead Sciences
This publication has 28 references indexed in Scilit:
- “Just Caring”: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?Journal of Personalized Medicine, 2013
- ‘Why is there another person's name on my infusion bag?’ Patient safety in chemotherapy care – A review of the literatureEuropean Journal of Oncology Nursing, 2013
- Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costsBMC Cancer, 2011
- Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacistsJournal of Applied Toxicology, 2011
- Electronic Prescribing at the Point of Care: A Time–Motion Study in the Primary Care SettingHealth Services Research, 2010
- Integration of prospective and retrospective methods for risk analysis in hospitalsInternational Journal for Quality in Health Care, 2009
- Medication Errors Among Adults and Children With Cancer in the Outpatient SettingJournal of Clinical Oncology, 2009
- Evaluation of Outpatient Computerized Physician Medication Order Entry Systems: A Systematic ReviewJournal of the American Medical Informatics Association, 2007
- Preventing Medication Errors in Hospitals through a Systems Approach and Technological Innovation: A Prescription for 2010Hospital Topics, 2006
- Medication safety in the ambulatory chemotherapy settingCancer, 2005